BRIEF-Bristol-Myers Squibb presents two-year overall survival data on Opdivo

* Two-Year overall survival data from two pivotal opdivo

(nivolumab) trials demonstrate sustained benefit in patients

with advanced non-small cell lung cancer

Read more